We discuss inference for data with repeated measurements at multiple levels. The motivating example are data with blood counts from cancer patients undergoing multiple cycles of chemotheraphy, with days nested within cycles. Some inference questions relate to repeated measurements over days within cycle, while other questions are concerned with the dependence across cycles.
Introduction
We consider semiparametric Bayesian inference for data with repeated measurements at multiple levels. The motivating data are blood count measurements for chemotherapy patients over multiple courses of chemotherapy. In earlier papers (Müller and Rosner, 1997; , we considered inference for the first course of chemotherapy only. Naturally, such data do not allow inference about changes between cycles. In clinical practice, however, cancer patients receive chemotherapy over multiple courses or cycles of predetermined duration. These courses of therapy typically consist of a period during which the patient receives active drug therapy, followed by a no-drug period to allow the patient to recover for the next round of chemotherapy. Often some aspect of the treatment protocol is intended to mitigate deterioration of the patient's performance across repeated treatment cycles. Inference related to such aspects of the treatment involves a comparison across cycles, which requires modeling of the entire data set, including data from later cycles. In this extended data set, repeated measurements occur at two levels. Each patient receives multiple cycles of chemotherapy, and within each cycle, measurements are recorded over time. Another typical example of this data structure is drug concentration measurements over repeated dosing studies of pharmacokinetics.
A standard parametric approach would base inference on conjugate distributions for the sampling model, hierarchical priors, and random effects distributions. Bayesian inference for such multilevel hierarchical models is reviewed, among many others, in Goldstein et al. (2002) who also discuss software for commonly used parametric models. Browne et al. (2002) compare Bayesian and likelihood-based methods.
The proposed semi-parametric Bayesian inference replaces traditional normal random effects distributions with nonparametric Bayesian models. Nonparametric Bayesian random effects distributions in mixed-effects models were first introduced in Bush and MacEachern (1996) . Applications to longitudinal data models are developed in Kleinman and Ibrahim (1998a) , Müller and Rosner (1997) and Walker and Wakefield (1998) , among many others. Kleinman and Ibrahim (1998b) extend the approach to allow binary outcomes, using generalized linear models for the top level likelihood. In each of these paper, the authors use variations of Dirichlet process (DP) models to define flexible nonparametric models for an unknown random effects distribution. The DP was introduced as a prior probability model for random probability measures in Ferguson (1973) or Antoniak (1974) . See these papers for basic properties of the DP model. A recent review of semiparametric Bayesian inference based on DP models appears in .
The rest of this article is organized as follows. In section 2, we introduce the proposed sampling model. In section 3, we focus on the next level of the hierarchy by proposing suitable models to represent and allow learning about dependence at the second level of the hierarchy. Section 4 discusses implementation of posterior simulation in the proposed model. Section 5 contains inference for the application that motivated this discussion. A final discussion section concludes the article.
First Level Repeated Measurement Model
In our semi-parametric Bayesian model representing repeated measurements at different levels of a hierarchy, the hierarchy follows the structure of the data. The key elements of the proposed approach are as follows. We consider two nested levels of measurement units, with each level giving rise to a repeated measurement structure. Assume data y ijk are recorded at times k, k = 1, . . . , n ij , for units j, j = 1, . . . , n i , nested within higher-level units i, i = 1, . . . , n. We will refer to the experimental units i as "subjects" and to experimental units j as "cycles" to simplify the following discussion and remind us of the motivating application.
We start by modeling dependence of the repeated measurements within a cycle, y ij = (y ijk , k = 1, . . . , n ij ):
We assume p(y ij | θ ij , η) to be a nonlinear regression parametrized by cycle-specific random effects θ ij . Here and throughout the following discussion, η are hyperparameters common across subjects i and cycles j. y ijk , measured over multiple cycles, with repeated measurements within each cycle. We define dependence within each cycle by assuming that observations arise according to some underlying mean function plus independent residuals
Here f is a nonlinear regression with parameters θ ij , and e ijk are assumed i.i.d. N (0, σ 2 ) normal errors. Marginalizing with respect to θ ij model (2) defines a dependent probability model for y ij . This use of random effects to introduce dependence in models for repeated measurement data is common practice. Choice of f (·; θ) is problem-specific. In the implementation reported later, we use a piecewise linear-linear-logistic function. In the absence of more specific information, we suggest the use of generic smoothing functions, such as spline functions (Denison et al., 2002) .
Second-Level Repeated Measurement Model
We introduce a dependent random effects distribution on (θ i1 , . . . , θ in i ) to induce dependence across cycles. We proceed with the most general approach, leaving the nature of the dependence unconstrained. We achieve this by considering a non-parametric prior for the joint distribution p(θ i1 , . . . , θ in i ). We use a non-parametric mixture prior. See details below. In this model, inference about dependence of the θ ij is essentially driven by the empirical distribution of the imputed cycle-specific random effects θ ij . The approach works well for continuous responses with a non-linear regression model (2), assuming the residual variance is small enough to leave little posterior uncertainty for the θ ij . We define a random effects distribution for
with a non-parametric prior on the mixing measure G. For later reference, we introduce the notation H(·) for the mixture model. As usual in mixture models, posterior inference proceeds with an equivalent hierarchical model:
Introducing the latent variables µ i , i = 1, . . . , n, replaces the mixture model with a hierarchical prior. The probability model for G is the main mechanism for learning about dependence across cycles. The proposed model is most easily described in terms of the prior predictive distribution. Assume patients i = 1, . . . , n have been observed. The prior predictive p(θ n+1 | θ 1 , . . . , θ n ) for patient n + 1 is of the following type. With some probability, θ n+1 is similar to one of the previously recorded patients. And with the remaining probability, θ n+1 is generated from a baseline distribution G defined below. The notion of "similarity"is formalized by assuming a positive prior probability for a tie of the latent variables µ i . Let k ≤ n denote the number of unique values among µ 1 , . . . , µ n and denote such values by µ
In words, the predictive distribution is a mixture of the empirical distribution of the already observed values and a base measure G . The relative weights are determined by weight functions w h . The predictive rule (4) is a defining property for a class of random probability measures known as species sampling models (SSM) (Pitman, 1996; Ishwaran and James, 2003) . Letting w = {w h } denote the weight functions, we write
The predictive rule (4) is attractive in many applications. For example, consider the application to the multi-cycle hematologic counts. The model implies that with some probability the response for the new patient replicates one the previous patient responses (up to residual variation), and with the remaining probability the response is generated from an underlying base measure G . The SSM includes the popular Dirichlet process (DP) as a special case with w h = m h /(M + n) and w k+1 = M/(M + n). We write DP (M, G ) for a DP model with base measure G and total mass parameter M . See, for example, for a review of DP mixture models as in (3). Because of its traditional use in nonparametric Bayesian inference, we suggest the DP as a default SSM specification, unless a particular set of weight functions is desired.
Inference in (3) is greatly simplified by assuming that the θ ij are independent given µ i . As before, letting θ i = (θ i1 , . . . , θ in i ), this assumption implies
In a Gibbs sampler implementation, the complete conditional posterior for the θ ij is conditionally independent of the data and parameters from other cycles and subjects. As a default choice for the density in (6), we suggest a kernel of the form
where µ i = (µ i1 , . . . , µ in i ) parallels the partitioning of θ i into cycle-specific subvectors. A typical choice is p(θ ij | µ ij , η) = N (µ ij , S), where S would be one of the hyperparameters included in η. Partitioning µ i = (µ i1 , . . . , µ in i ) naturally leads us to use the same factorization as in (6) for the base measure G :
The advantage of this choice of base measure is that hyperparameters η that define G only need to be defined for the random vector µ ij instead of the higher dimensional vector µ i . For example, consider a multivariate normal base measure N (x; m, S) for random vector x with moments (m, S). Using G (µ i ) = N (µ ij ; m, B), we only need to specify the moments (m, B) for the lower dimensional subvector µ ij . Using a base measure (7) with conditional independence across cycles, any inference about dependence across cycles for a future patient arises from the data-driven clustering of the imputed µ i vectors. Clustering over locations allows modeling dependence in much the same way as a mixture of bivariate standard normals kernel can approximate any bivariate distribution, with arbitrary variance-covariance matrix, in a bivariate kernel density estimate.
Posterior Inference
Consider the SSM mixture model (4) and (6). We assume a multivariate normal kernel, with µ i partitioned as µ i = (µ i1 , . . . , µ in i ) and a kernel
The common covariance matrix S is part of the hyperparameter vector η. The use of the normal kernel reduces posterior inference for θ ij to the traditional problem of normal nonlinear regression with normal priors (conditional on the mixing variable µ i and the hyperparameters η). An important feature of the model is the conditional independence of the θ ij across cycles j given µ i and η. This allows us to consider one cycle at a time when updating θ ij in the Gibbs sampler. Details of the conditional posterior distribution for θ ij and the choice of a suitable MCMC move depend on the nature of (2). Choosing the base measure G for the nonparametric prior, we use a conjugate prior to the kernel p(θ ij | µ ij , η) in the base measure. This greatly simplifies posterior simulation for the µ ij . As usual in SSMs, posterior inference proceeds in the marginal model (4), after analytically integrating out the random measure G. Posterior simulation in this model is straightforward. See, for example, , Neal (2000) , or Jain and Neal (2004) The references are specific to the DP model but are easily modified to the SSM by using the appropriate prior predictive weights given in (4). See also Ishwaran and James (2003) and references therein.
In many applications, the number of cycles n i varies across subjects. This poses no problem in the SSM model. Letn denote the maximum across all subjects. First consider a model with parameters θ ij , j = 1, . . . ,n, for all patients. The fact that the likelihood does not include θ ij , j = n i + 1, . . . ,n, poses no difficulty. Next, note that θ ij , j > n i , is easily marginalized analytically, allowing us to use only θ ij , j = 1, . . . , n i , in the actual implementation.
A minor modification of the model allows us to include cycle-specific covariates. Let x ij denote a vector of covariates for cycle j of patient i. This could, for example, include dose of a treatment in cycle j. A straightforward way to include a regression on x ij is to extend the probability model on θ ij to a probability model onθ ij ≡ (x ij , θ ij ). The implied conditional distribution p(θ ij | x ij ) formalizes the desired density estimation for θ as a function of x. This approach is used, for example, in Mallet et al. (1988) and Müller and Rosner (1997) .
Modeling Multiple Cycle Hematologic Data
Modeling patient profiles (e.g., blood counts, drug concentrations, etc.) over multiple treatment cycles requires a hierarchical extension of a basic one-cycle model. Model (2) together with (3), with θ i including random effects for all cycles, provides such a generalization. Several important inference questions can only be addressed in the context of a joint probability model across multiple cycles. For example, in a typical chemotherapy regimen, some aspects of the proposed treatment are aimed at mitigating deterioration of the patient's overall performance over the course of the treatment. Immunotherapy, growth factors, or other treatments might be considered to ensure reconstitution of blood cell counts after each chemotherapy cycle.
We analyze data from a phase I clinical trial with cancer patients carried out by the Cancer and Leukemia Group B (CALGB), a cooperative group of university hospitals funded by the U.S. National Cancer Institute to conduct studies relating to cancer therapy. The trial, CALGB 8881, was conducted to determine the highest dose of the anti-cancer agent cyclophosphamide (CTX) one can safely deliver every two weeks in an outpatient setting (Lichtman et al., 1993) . The drug is known to cause a drop in white blood cell counts (WBC). Therefore, patients also received GM-CSF, a colony stimulating factor given to spur regrowth of blood cells (i.e., for hematologic support). The protocol required fairly extensive monitoring of patient blood counts during treatment cycles. The number of measurements per cycle varied between 4 and 18, with an average of 13. The investigators treated cohorts of patients at different doses of the agents. Six patients each were treated at the following combinations (CTX, GM-CSF) of CTX (in g/m 2 ) and GM-CSF (in µg/kg): (1.5, 10), (3.0, 2.5), (3.0, 5.0), (3.0, 10.0) and (6.0, 5.0). Cohorts of 12 and 10 patients, respectively, were treated at dose combinations of (4.5, 5.0) and (4.5, 10.0). Hematologic toxicity was the primary endpoint. In Müller and Rosner (1997) and , we reported analyses restricted to data from the first treatment cycle. However, the study data include responses over several cycles for many patients, allowing us to address questions related to changes over cycles. We use the model proposed in Sections 2 and 3 to analyze the full data. The data are WBC in thousands, on a logarithmic scale, y ijk = log(WBC/1000), recorded for patient i, cycle j, on day t ijk . The times t ijk are known, and reported as days within cycle. We use a non-linear regression to set up p(y ij | θ ij , η). For each patient and cycle, the response y ij = (y ij1 , . . . , y ijn ij ) follows a typical "bath tub" pattern, starting with an initial base line, followed by a sudden drop in WBC at the beginning of chemotherapy, and eventually a slow S-shaped recovery. In Müller and Rosner (1997) we studied inference for one cycle alone, using a non-linear regression (2) in the form of a piecewise linear and logistic curve. The mean function f (t; θ) is parameterized by a vector of random effects θ = (z 1 , z 2 , z 3 , τ 1 , τ 2 , β 1 ):
where
The intercept in the logistic regression was fixed at 2.0 after finding in a preliminary data analysis that a variable intercept did not significantly improve the fit. We again use model (9) and assume model (6), θ ij ∼ N (µ ij , S), independently across patients i and cycles j. Dependence across cycles is introduced by the nonparametric prior µ i ∼ G. Specifying the SSM prior for G, we use the predictive rules corresponding to the DP prior, i.e., G ∼ DP (M, G ). Finally, we include a regression on covariates x ij . We use the bivariate covariate of the treatment doses of CTX and GM-CSF in cycle j, patient i. Both doses are centered and scaled to zero mean and standard deviation 1.0 using the empirical mean and standard deviation across the n = 52 patients.
We complete the model with prior specifications for the hyperparameters η. For the residual variance σ 2 we assume σ −2 ∼ Gamma(a/2, ab/2), parametrized such that E(σ −2 ) = 1/b, with a = 10 and b = 0.01. Let diag(x) denote a diagonal matrix with diagonal elements x. For the covariance matrix of the normal kernel in (8), we use S −1 ∼ W (q, R −1 /q) with q = 25 degrees of freedom and R = diag(0.01, 0.01, 0.1, 0.1, 0.1, 0.01, 1, 1). The elements of θ ij are arranged such that the first two elements correspond to the covariate x ij and the third through eighth elements correspond to the parameters in the non-linear regression (9), z 1 , z 2 , z 3 , τ 1 , τ 2 and β 1 . The base measure G of the DP prior is assumed multivariate normal 
, and the hyperprior mean is fixed as the average of single patient maximum likelihood estimates (m.l.e.). Let θ i1 denote the m.l.e. for patient i. We use d = 1/n θ i1 . Finally, the total mass parameter is assumed M ∼ Gamma(5, 1). We implemented posterior MCMC simulation to carry out inference in model (2), (3) and (5), using with the described prior and hyperprior choices. The parameter σ 2 , S, B, m and B are updated by draws from their complete conditional posterior distributions. All are standard probability models that allow efficient random variate generation. Updating the latent variables µ i , i = 1, . . . , n and the total mass parameter M proceeds as described in . Finally, consider updating θ i . Conditional on µ i , inference in the model is unchanged from the single-cycle model. Updating the random effects parameters θ ij in a posterior Markov chain Monte Carlo (MCMC) simulation reduces to a nonlinear regression defined by the sampling model (9) and the normal prior θ ij ∼ N (µ ij , S). In particular, for the coefficients in θ ij corresponding to the random effects parameters z 1 , z 2 and z 3 , the complete conditional posterior is available in closed form as the posterior in a normal linear regression model.
Posterior inference is summarized in Figures 2 through 4. Recall that H(θ
denotes the nonparametric mixture model for the random effects distribution. Also, we use Y to denote all observed data. Note that the posterior expectation E(H | Y ) is identical to the posterior predictive p(θ n+1 | Y ) for a new subject:
The high dimensional nature of θ ij makes it impractical to show the estimated random effects distribution itself. Instead we show the implied WBC profile as a relevant summary. Figure 2 shows posterior predictive WBC counts for a future patient, arranged by dose x ij and cycle j. Each panel shows posterior predictive inference for a different dose of CTX and GM-CSF, assuming a constant dose across all cycles. Within each panel, three curves show posterior predictive mean responses for cycles j = 1 through j = 3. Each curve shows E(y n+1,jk | Y ), plotted against t n+1,jk . Together, the three curves summarize what was learned about the change of θ ij across cycles. Note how the curve for the third cycle (j = 3) deteriorates by failing to achieve the recovery to baseline WBC. Comparing the predicted WBC profiles for high versus low dose of GM-CSF for the same level of CTX confirms that the growth factor worked as intended by the clinicians. The added GM-CSF improves the recovery to baseline for later cycles. Figure 3a summarizes an important feature of G. Let p14 denote the probability of white blood cell count (WBC) above a critical threshold of 1000 on day 14, i.e., p14 = p(Y n+1,jk > log 1000 | Y ) for t n+1,jk = 14 (we modeled log WBC). The figure plots p14 against cycle, arranged by treatment level x n+1 (assuming constant treatment level across all cycles and denoting the common value by x n+1 ). For each cycle j and treatment level the lines show the marginal posterior predictive probability of a WBC beyond 1000 by day 14. Figure 3b plots the posterior predictive minimum WBC (in log 1000) by cycle within doses of the two drugs. Figure 4 shows another summary of the estimated model H(θ), across cycles, for fixed doses, CTX= 3g/m 2 and GM-CSF= 5µg/kg. We consider two clinically relevant summaries, the nadir WBC and the number of days that WBC is below a critical threshold of 1000 (TLO). Both summaries are evaluated for each cycle. For each summary statistic we show the joint distribution for cycles 1 and 2. The bivariate distributions are visualized by plotting 500 random draws.
Conclusion
We have introduced semiparametric Bayesian inference for multi-level repeated measurement data. The nonparametric nature of the model are the random effects distribution for the first level random effects and the probability model for the joint distribution of random effects across second level repetitions. The main limitation of the proposed approach is the computation-intensive implementation. The computational effort is in inference about possible configurations of ties of the latent variables, as in any DP mixture model. The probability model on the configuration indicators is easy to describe, but implementation involves manipulation of cluster memberships and keeping track of a variable number of unique values.
Regression on cycle-specific covariates x ij was accommodated by extending the random effects distribution to a joint vector of covariates and random effects. The implied conditional distribution of random effects given covariates formalizes the desired regression. This construction, while traditional, raises the possible concern of including a model on covariates that might have been fixed by design. An alternative construction could use the model proposed in De Iorio et al. (2004) to introduce a covariate in the DP prior for G by defining a dependent DP (DDP) model (MacEachern, 2001) . Everything else would remain unchanged.
Two other important directions of extensions for the proposed model are to different data formats, for example repeated binary data, and to a more structured model for the dependence across cycles. In the proposed model, dependence across cycles is essentially learned by clustering of the imputed random effects vectors for the observed patients. The approach works well for continuous responses with a non-linear regression model (2), assuming the residual variance is small enough to leave little posterior uncertainty for the θ ij . The model is not appropriate for less informative data, for example binary data. As a more structured alternative, we would suggest keeping the non-parametric random effects model for the first cycle random effects only and assuming a suitable parametric model for the later cycle random effects. For example, one could assume an autoregressive model for θ ij conditional on θ i,j−1 . In this case the nature of the dependence across cycles is fixed, and the model only allows learning about the strength of this relationship, for example by learning about the autoregressive coefficients.
An extension to binary repeated measurements requires replacing the top level repeated measurement model. For example, the sampling model could be based on the notion of order-exchangeability. Order-exchangeability defines a non-parametric probability model for binary sequence data that imposes minimal structure while still allowing inference about dependence (Quintana and Newton, 1998) . Order-exchangeability implies a mixture homogeneous Markov chains. The mixture is with respect to the order-transition probabilities. Letting θ ij denote the set of transition probabilities, the model fits into the remaining structure of the probability model proposed earlier. We are currently working on this approach. Alternatively, for reasons of simplicity and practical feasibility, one could use a parsimonious parametrization of the transition probabilities.
Finally, in the proposed inference we did not model informative censoring. For example, in the data set of multi-course chemotherapy patients, it is plausible that patients drop out from the treatment for reasons related to the observed response. It would be straightforward to add a factor in the likelihood to model the time to withdrawal from the study. This extension to the model is an area of our on-going research. . We show the bivariate marginals for cycle 1 and 2 for two relevant summaries of θ, for doses CTX=3 g/m 2 and GM-CSF=5 µg/kg. The left panel shows the estimated distribution of T lo , the number of days that WBC is below 1000, for the first two cycles. The right panel shows the same for the minimum WBC (in log 1000). The distributions are represented by scatterplots of 500 simulated draws. For the integer valued variable T lo we added additional noise to the draws to visualize multiple draws at the same integer pairs.
